Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-009278-29-BE

Enrollment

Registered

2009-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular and neurological diseases, associated with obesity and insulin resistance MedDRA version: 9.1 Level: LLT Classification code 10022489 Term: Insulin resistance MedDRA version: 9.1 Level: PT Classification code 10022489 Term: Insulin resistance MedDRA version: 9.1 Level: LLT Classification code 10029883 Term: Obesity MedDRA version: 9.1 Level: PT Classification code 10065941 Term: Central obesity

Interventions

Product Name: Metformin Product Code: A10BA02 Pharmaceutical Form: Capsule, hard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adolescents with neurological or neuromuscular diseases Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: type 1 diabetes Liver failure Kidney failure

Design outcomes

Primary

Measure	Time frame
Main Objective: Effect of metformin on body composition and insulin resistance;Secondary Objective: ;Primary end point(s): insulin resistance fat percentage weight	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026